Nrx pharmaceuticals provides progress update on interactions with the fda regarding path to nda submission for nrx-101

Radnor, pa. , jan. 19, 2023 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage central nervous system (cns) biopharmaceutical company, today announced that it had a meeting and a written response from the food and drug administration (fda) last week regarding its lead compound, nrx-101.
NRXP Ratings Summary
NRXP Quant Ranking